- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nuvectis Pharma Inc (NVCT)
Assess today's live Nuvectis Pharma Inc (NVCT) share price, performance and insights using our live NASDAQ: NVCT stock exchange data.
Analyse the historical data and Nuvectis Pharma Inc share price performance charts on this page. Our technical summary section provides analysis on Nuvectis Pharma share price buy/sell indicators using real-time data (or discuss the Nuvectis Pharma (NVCT) stock price today with other investors in the Nuvectis Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NVCT share price (ISIN: US67080T1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Nuvectis Pharma Inc Share Price Today?
The Nuvectis Pharma share price today is 8.57.
What Is the Stock Symbol for Nuvectis Pharma Inc
The stock symbol (or 'ticker') for Nuvectis Pharma Inc is "NVCT."
What Stock Exchange Does Nuvectis Pharma Inc Trade On?
Nuvectis Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is Nuvectis Pharma Inc a Good Stock to Buy?
Determining whether Nuvectis Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Nuvectis Pharma Inc share price performance charts on this page. Our technical summary section provides analysis on Nuvectis Pharma share price buy/sell indicators using real-time data (or discuss the Nuvectis Pharma (NVCT) stock price today with other investors in the Nuvectis Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ NVCT share price (ISIN: US67080T1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Nuvectis Pharma Inc Share Price Today?
The Nuvectis Pharma share price today is 8.57.
What Is the Stock Symbol for Nuvectis Pharma Inc
The stock symbol (or 'ticker') for Nuvectis Pharma Inc is "NVCT."
What Stock Exchange Does Nuvectis Pharma Inc Trade On?
Nuvectis Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is Nuvectis Pharma Inc a Good Stock to Buy?
Determining whether Nuvectis Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
8.57
+0.07(+0.82%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.44
8.64
52 wk Range
5.55
11.15
Earnings results expected in 12 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.448.64
52 wk Range
5.5511.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVCT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
16.80
Upside
+96.03%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form S-3 Nuvectis Pharma Inc For: 14 February
- Investing.com
- Form S-3 Nuvectis Pharma Inc For: 14 February
- Investing.com
- Form 8K Nuvectis Pharma Inc For: 11 February
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 16.80
(+96.03% Upside)
Earnings
Latest Release
12/02/2026
EPS / Forecast
-0.31 / -0.25
Revenue / Forecast
-- / --
Compare NVCT to Peers and Sector
Metrics to compare | NVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −7.9x | −2.7x | −0.5x | |
PEG Ratio | 0.40 | 0.02 | 0.00 | |
Price/Book | 12.3x | 2.5x | 2.6x | |
Price / LTM Sales | - | 12.5x | 3.2x | |
Upside (Analyst Target) | 111.8% | 110.0% | 50.8% | |
Fair Value Upside | Unlock | 11.1% | 7.7% | Unlock |
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Nuvectis Pharma (NASDAQ: NVCT) Share Price Today?
The Nuvectis Pharma stock price today is 8.57 USD.
What Stock Exchange Does Nuvectis Pharma (NVCT) Trade On?
Nuvectis Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Nuvectis Pharma?
The stock symbol (also called a 'ticker') for Nuvectis Pharma is "NVCT."
What Is the Current Nuvectis Pharma Market Capitalisation?
As of today, Nuvectis Pharma (NASDAQ: NVCT) market cap is 225.18M USD.
What Is Nuvectis Pharma's (NVCT) Earnings Per Share (TTM)?
The Nuvectis Pharma EPS is currently -1.32 (Trailing Twelve Months).
When Is the Next Nuvectis Pharma Earnings Date?
Nuvectis Pharma's next earnings report will be released on 12/05/2026.
Is NVCT a Buy or Sell From a Technical Analyst Perspective?
Based on today's Nuvectis Pharma moving averages and other technical indicators, the daily buy/sell signal for NVCT stock is Buy.
How Many Times Has Nuvectis Pharma Stock Split?
Nuvectis Pharma has split 0 times. (See the NVCT stock split history page for full effective split date and price information.)
How Many Employees Does Nuvectis Pharma Have?
Nuvectis Pharma has 13 employees, based on their latest Companies House report.
What is the current trading status of Nuvectis Pharma (NASDAQ: NVCT)?
As of 30/04/2026, Nuvectis Pharma (NVCT) is trading at a share price of 8.57 USD, with a previous close of 8.50 USD. The stock has fluctuated within a day range of 8.44 USD to 8.64 USD, while its 52-week range spans from 5.55 USD to 11.15 USD.
What Is Nuvectis Pharma (NVCT) Price Target According to Analysts?
The average 12-month price target for Nuvectis Pharma is 16.80 USD, with a high estimate of 20 USD and a low estimate of 10 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +96.03% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.